Tag: boehringer ingelheim
NOAC reversal agent shows rapid and complete reversal of dabigatran
Boehringer Ingelheim has announced results from two new analyses of the phase III RE-VERSE AD study, which evaluated the safety and efficacy of idarucizumab,...
Final Phase III results support safety of idarucizumab as reversal agent...
Final results from RE-VERSE AD study show that idarucizumab, marketed in the US as Praxbind (Boehringer Ingelheim), was able to immediately reverse the anticoagulant...